S Eberl1,2, A Katsifis3,4, M A Peyronneau5, L Wen3,6, D Henderson3, C Loc'h3, I Greguric7, J Verschuer3, T Pham7, P Lam3, F Mattner3, A Mohamed3,8, M J Fulham3,6,8. 1. Department of Molecular Imaging (PET and Nuclear Medicine), Royal Prince Alfred Hospital, Building 63, Level A7, Missenden Road, Camperdown, NSW, 2050, Australia. stefan.eberl@sydney.edu.au. 2. Faculty of Engineering and Information Technologies, University of Sydney, Sydney, NSW, 2006, Australia. stefan.eberl@sydney.edu.au. 3. Department of Molecular Imaging (PET and Nuclear Medicine), Royal Prince Alfred Hospital, Building 63, Level A7, Missenden Road, Camperdown, NSW, 2050, Australia. 4. Faculty of Pharmacy, University of Sydney, Sydney, NSW, 2006, Australia. 5. IMIV, CEA, Inserm, Univ. Paris-Sud, CNRS, Université Paris-Saclay, CEA-SHFJ, Orsay, France. 6. Faculty of Engineering and Information Technologies, University of Sydney, Sydney, NSW, 2006, Australia. 7. Radiochemistry and Radiotracers Platform, ANSTO, New Illawarra Road, Lucas Heights, NSW, 2234, Australia. 8. Sydney Medical School, University of Sydney, Sydney, NSW, 2006, Australia.
Abstract
PURPOSE: To determine the metabolic profiles of the translocator protein ligands PBR102 and PBR111 in rat and human microsomes and compare their in vivo binding and metabolite uptake in the brain of non-human primates (Papio hamadryas) using PET-CT. METHODS: In vitro metabolic profiles of PBR102 and PBR111 in rat and human liver microsomes were assessed by liquid chromatography-tandem mass spectrometry. [18F]PBR102 and [18F]PBR111 were prepared by nucleophilic substitution of their corresponding p-toluenesulfonyl precursors with [18F]fluoride. List mode PET-CT brain imaging with arterial blood sampling was performed in non-human primates. Blood plasma measurements and metabolite analysis, using solid-phase extraction, provided the metabolite profile and metabolite-corrected input functions for kinetic model fitting. Blocking and displacement PET-CT scans, using PK11195, were performed. RESULTS: Microsomal analyses identified the O-de-alkylated, hydroxylated and N-de-ethyl derivatives of PBR102 and PBR111 as the main metabolites. The O-de-alkylated compounds were the major metabolites in both species; human liver microsomes were less active than those from rat. Metabolic profiles in vivo in non-human primates and previously published rat experiments were consistent with the microsomal results. PET-CT studies showed that K1 was similar for baseline and blocking studies for both radiotracers; VT was reduced during the blocking study, suggesting low non-specific binding and lack of appreciable metabolite uptake in the brain. CONCLUSIONS: [18F]PBR102 and [18F]PBR111 have distinct metabolic profiles in rat and non-human primates. Radiometabolites contributed to non-specific binding and confounded in vivo brain analysis of [18F]PBR102 in rodents; the impact in primates was less pronounced. Both [18F]PBR102 and [18F]PBR111 are suitable for PET imaging of TSPO in vivo. In vitro metabolite studies can be used to predict in vivo radioligand metabolism and can assist in the design and development of better radioligands.
PURPOSE: To determine the metabolic profiles of the translocator protein ligands PBR102 and PBR111 in rat and human microsomes and compare their in vivo binding and metabolite uptake in the brain of non-human primates (Papio hamadryas) using PET-CT. METHODS: In vitro metabolic profiles of PBR102 and PBR111 in rat and human liver microsomes were assessed by liquid chromatography-tandem mass spectrometry. [18F]PBR102 and [18F]PBR111 were prepared by nucleophilic substitution of their corresponding p-toluenesulfonyl precursors with [18F]fluoride. List mode PET-CT brain imaging with arterial blood sampling was performed in non-human primates. Blood plasma measurements and metabolite analysis, using solid-phase extraction, provided the metabolite profile and metabolite-corrected input functions for kinetic model fitting. Blocking and displacement PET-CT scans, using PK11195, were performed. RESULTS: Microsomal analyses identified the O-de-alkylated, hydroxylated and N-de-ethyl derivatives of PBR102 and PBR111 as the main metabolites. The O-de-alkylated compounds were the major metabolites in both species; human liver microsomes were less active than those from rat. Metabolic profiles in vivo in non-human primates and previously published rat experiments were consistent with the microsomal results. PET-CT studies showed that K1 was similar for baseline and blocking studies for both radiotracers; VT was reduced during the blocking study, suggesting low non-specific binding and lack of appreciable metabolite uptake in the brain. CONCLUSIONS: [18F]PBR102 and [18F]PBR111 have distinct metabolic profiles in rat and non-human primates. Radiometabolites contributed to non-specific binding and confounded in vivo brain analysis of [18F]PBR102 in rodents; the impact in primates was less pronounced. Both [18F]PBR102 and [18F]PBR111 are suitable for PET imaging of TSPO in vivo. In vitro metabolite studies can be used to predict in vivo radioligand metabolism and can assist in the design and development of better radioligands.
Authors: Thomas Bourdier; David Henderson; Christopher J R Fookes; Peter Lam; Filomena Mattner; Michael Fulham; Andrew Katsifis Journal: Appl Radiat Isot Date: 2014-03-18 Impact factor: 1.513
Authors: H Umesha Shetty; Sami S Zoghbi; Fabrice G Siméon; Jeih-San Liow; Amira K Brown; Pavitra Kannan; Robert B Innis; Victor W Pike Journal: J Pharmacol Exp Ther Date: 2008-09-19 Impact factor: 4.030
Authors: G Trapani; M Franco; A Latrofa; L Ricciardi; A Carotti; M Serra; E Sanna; G Biggio; G Liso Journal: J Med Chem Date: 1999-09-23 Impact factor: 7.446
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Emmanuelle Briard; Sami S Zoghbi; Fabrice G Siméon; Masao Imaizumi; Jonathan P Gourley; H Umesha Shetty; Shuiyu Lu; Masahiro Fujita; Robert B Innis; Victor W Pike Journal: J Med Chem Date: 2009-02-12 Impact factor: 7.446
Authors: Thomas Keller; Francisco R López-Picón; Anna Krzyczmonik; Sarita Forsback; Jatta S Takkinen; Johan Rajander; Simo Teperi; Frédéric Dollé; Juha O Rinne; Merja Haaparanta-Solin; Olof Solin Journal: J Cereb Blood Flow Metab Date: 2019-05-29 Impact factor: 6.200
Authors: Filomena Mattner; Andrew Katsifis; Thomas Bourdier; Christian Loc'h; Paula Berghofer; Christopher Fookes; Tzong-Tyng Hung; Timothy Jackson; David Henderson; Tien Pham; Brendan J Lee; Rachael Shepherd; Ivan Greguric; Naomi Wyatt; Thanh Le; Jackson Poon; Carl Power; Michael Fulham Journal: RSC Med Chem Date: 2021-04-19